Cellectis S.A.   Report issue

For profit Phase 1 Phase 2
Founded: Paris France (1999)

Organization Overview

First Clinical Trial
2017
NCT03190278
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cellectis S.A.

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: Cellectis S.A. (2) Acquired (3)

alemtuzumab (campath) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

pvaxrcpsav53l (1 trial)

sargramostim (leukine) (1 trial)

ucart20x22 (1 trial)

Drugs in Phase 1 Trials (4)

Key: Cellectis S.A. (3) Acquired (1)

cd22 car-t cells (1 trial)

erythromycin (ilosone) (1 trial)

ucart123 (3 trials)

ucartcs1a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 9